Q2 2025 EARNINGS RELEASE June 5, 2025 THE TORO COMPANY Cautionary Note This presentation contains forward-looking statements, which are being made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward- looking statements are based on management's current assumptions and expectations of future events and often can be identified by words such as "believe," "expect," "intend," "forward," "future," "goal," "guidance," "improve," "may," "outlook," "should," ...

Core Viewpoint - Archer Aviation is preparing to ramp up production of its Midnight eVTOL aircraft in 2025, aiming for long-term growth despite currently not generating any revenue [1][2][12] Company Overview - Archer Aviation is currently focused on manufacturing and testing its eVTOL aircraft, with its income statement reflecting only operating expenses due to the absence of revenue [2] - The Midnight aircraft is designed for short-distance travel as an air taxi, representing a new category of aircraft that is still being understood by regulatory bodies like the FAA [4] Recent Developments - Archer Aviation has received FAA clearance to operate an airline and train pilots, and has established deals for air taxi services in California and New York [5] - The company plans to carry its first commercial customers in Abu Dhabi in 2025, where regulations are less restrictive, allowing for valuable operational insights [6][7] Market Expansion - Archer Aviation is exploring military applications for its eVTOL aircraft through a partnership with Anduril Industries, aiming to penetrate a complex market with significant safety and political considerations [8] - The collaboration will investigate civil and defense applications in the U.K., including logistics for cargo transport, which could enhance the aircraft's market potential [9][10][11] Strategic Focus - The company is diversifying its potential use cases for the Midnight aircraft, which may increase its long-term success by tapping into various markets [11] - Monitoring developments in Abu Dhabi and other initiatives, such as military opportunities and logistics, is crucial for understanding the company's growth trajectory [13]

ARS Pharmaceuticals (SPRY) FY Conference June 03, 2025 12:20 PM ET Speaker0 Thank you very much. One sec. I'll just Speaker1 just briefly I'm Lachlan Henry Brown, one of the research analysts here at William Blair. Along with my colleague, Matt Phipps, we cover ARS Pharmaceuticals. Before I hand it over to Richard Lowenthal, the president and CEO of the company, did want to just mention, please visit WilliamBlair.com to see any and all relevant disclosures. And with that, I'll pass it on to Rich. Take it aw ...

Core Insights - Tesla is set to launch its first robotaxi service in Austin, TX, with a tentative start date of June 12, marking a significant step into the autonomous vehicle market [1][2] - The robotaxi service will utilize Tesla's Full Self-Driving (FSD) software, with CEO Elon Musk stating that Model Y vehicles are already being tested on public roads without a driver [2] - Despite the excitement, there are concerns regarding the lack of detailed information about the service's operational aspects, including vehicle deployment and safety measures [3][11] Tesla's Competitive Position - Tesla faces stiff competition from Waymo, which currently leads the U.S. robotaxi market, operating commercial services in four cities and providing over 250,000 paid rides weekly [6] - Waymo has adopted a cautious approach, focusing on data collection and safety studies, while Tesla has relied on bold claims from its CEO without substantial public data [7][20] - Tesla's robotaxis are expected to have a cost advantage, with production costs estimated at $50,000 compared to Waymo's $180,000 due to Tesla's reliance on cameras instead of high-end sensors [9] Market Challenges - Tesla is experiencing declining deliveries and increased competition from both legacy automakers and new entrants like BYD, which has surpassed Tesla in EV deliveries for two consecutive quarters [12][13] - The company has been offering deep discounts to boost demand, which is negatively impacting profit margins, leading to a reduction in growth targets for 2025 [14] - Tesla's stock has seen a 23% increase recently, likely due to optimism surrounding the robotaxi launch, but much of this may already be priced into the stock [4][22] Valuation Concerns - Tesla's forward price/sales ratio stands at 10.69, significantly higher than the industry average of 2.77, raising concerns about overvaluation [16] - The market appears to be pricing in expectations for breakthroughs in high-risk areas like autonomous driving, which remain unproven [18][21] - Given the current challenges in Tesla's core EV business and the uncertainties surrounding the robotaxi launch, the investment case appears weaker [21][22]

本期投资提示： （一）禾赛科技：一季度交付量近20 万台，同比高增231%。禾赛科技公布2025 年第一季度财务数据， 数据显示第一季度实现营收5.3 亿元，同比增长46.3%。2025 年第一季度，禾赛激光雷达总交付量为 19.58 万台，同比增长231.3%。其中，ADAS 产品交付量为14.61 万台同比增长178.5%。机器人领域交 付量增长迅猛，在Robotaxi 领域和消费级机器人领域均加速市场渗透进程。在Robotaxi 市场，禾赛作为 百度ApolloGo、滴滴自动驾驶、小马智行和文远知行等头部Robotaxi 企业下一代车队的主激光雷达供应 商。在消费级机器人市场，公司将交付30 万颗JT 系列激光雷达加速渗透。 控制器板块此前超跌较为显著，且基本面边际向好显著，有望实现业绩修复和估值修复双击。就控制器 板块代表公司和而泰和拓邦股份来看，2025Q1 业绩已呈现修复态势，可乐观展望后续季度业绩表现。 复盘历史十年控制器板块代表公司和而泰和拓邦股份股价表现，我们认为： （1）控制器板块股价表现对业绩敏感度较高，业绩对原材料价格变动敏感度高。在18年、 21-23 年期 间，控制器部分原材料（包 ...

Core Viewpoint - Theravance Biopharma has entered into a definitive agreement to sell its remaining royalty interest in Trelegy Ellipta to GSK for $225 million in cash, translating confidence in Trelegy's sustained success into immediate value for shareholders [1][2] Financial Summary - The sale of Outer Year Royalties will provide Theravance Biopharma with $225 million in cash, in addition to the $1.1 billion received from the initial sale of Trelegy royalty interests in 2022, bringing the total potential lifetime value from Trelegy monetization efforts to $1.525 billion [3][6] - The company retains rights to receive up to $150 million in remaining Trelegy sales-related milestones in 2025 and 2026 from Royalty Pharma, with minimal growth required over 2024 actuals to achieve these milestones [3][6] Strategic Review Committee - This transaction is the first outcome of the ongoing efforts of the Strategic Review Committee formed by the Board of Directors to assess strategic alternatives and enhance shareholder value [4] - The Committee will continue to evaluate various alternatives to maximize shareholder value, although there is no assurance that additional transactions will occur [4] Product Development - Theravance Biopharma is focused on growing YUPELRI and advancing ampreloxetine towards potential regulatory approval and launch, indicating a commitment to developing its product pipeline [2][8]

Company Overview - Archer Aviation has developed an electric vertical takeoff and landing (eVTOL) aircraft named Midnight, designed for short-distance travel as an air taxi [2] - The company aims to produce up to 10 Midnight eVTOLs in 2025, primarily for the FAA approval process [4] Regulatory Environment - The airline industry is highly regulated, and obtaining FAA clearance for new aircraft is a lengthy multistep process [4] - As of the end of Q1 2025, Archer Aviation was only 15% through the FAA approval process, indicating significant work remains before Midnight can fly in the U.S. [5] International Operations - A key focus for Archer Aviation in 2025 is to launch its first commercial air taxi service in Abu Dhabi, which will serve as a critical test for its business model [6] - Successful operations in Abu Dhabi could provide a blueprint for domestic air taxi services in the U.S. and increase consumer confidence in the new aircraft [9] Market Potential - The stock price of Archer Aviation could rise significantly if the air taxi service in Abu Dhabi is successfully launched, potentially surpassing its 52-week high of $13.30 per share [7][11] - The company has already established a foundation for operating air taxis in the U.S., having received FAA approval to operate as an airline and to train pilots [8]

Core Viewpoint - Tesla's stock has experienced significant volatility in 2025, with shares fluctuating between $220 and $430, yet the company's growth narrative remains strong, supported by two key factors that suggest potential investment before the upcoming earnings call in late July [1] Group 1: Capital Advantage - Tesla possesses a substantial capital advantage, which is critical in the electric vehicle (EV) sector where many competitors have failed due to financial constraints [2] - The capital and time required to bring an EV to market are often underestimated; Tesla's journey from inception to market was relatively swift compared to competitors like Rivian and Lucid Motors [3] - Currently, Tesla is the largest pure-play EV company in North America, with a market capitalization of approximately $1 trillion, while Rivian and Lucid Group together are valued at only $30 billion [4] - Tesla's ability to raise $30 billion in new cash by diluting shareholders by just 2.5% enhances its financial stability and lowers its cost of debt, providing a significant competitive edge [4][5] Group 2: Robotaxi Growth Opportunity - The introduction of Tesla's robotaxi service, starting with the Cybercab and initially utilizing Model Ys, is seen as a major growth opportunity, with expectations of dominating the U.S. ride-hailing market [7] - Investor Cathie Wood predicts that the robotaxi service could significantly increase Tesla's stock price and contribute over 90% of the company's revenues in the long term, potentially reaching $1.7 trillion by 2040 [7][9] - Despite skepticism regarding the timelines for the robotaxi service's rollout, Tesla's capital advantages provide the necessary resources to develop and scale this initiative over the coming years [8][9]

正是 得益于高毛利的机器人产品销量翻倍 以及 自研芯片带来的成本优势 和 产品组合优化 ， 速腾 聚创 一季度的毛利率同比 提升 11.2个百分点 至 23.5% 。同时， 速腾聚创一季度 的 净亏损显著 收窄至 9878.6万元，同比改善24.4% 。 机器人业务爆发成新引擎，数字化激光雷达引领全场景落地。 本文为IPO早知道原创 作者｜Stone Jin 微信公众号｜ipozaozhidao 据 IPO早知道消息， RoboSense速腾聚创（2498.HK） 于 5月30日 发布 了 2025年第一季度未 经审核的财务业绩公告。 财报显示， 速腾聚创 今年 一季度实现营收 3.28亿元 （人民币，下同） 。其中， ADAS激光雷达 收入2.29亿元；泛机器人激光雷达收入0.73亿元，同比 增长 87%；解决方案及其他收入0.26亿 元，同比增长61%。 值得注意的是， 速腾聚创 一季度 机器人产品销量 为 11,900台，同比 大幅增长 183.3% 。 这里 需要指出的一点是， 速腾聚创 的 E1R 、 Airy激光雷达产品毛利率 高于 Ruby、Helios 、 Bpearl 系列等机械式激光雷达产 ...

导读 ： 荣耀进军机器人赛道；多家公司加速布局Robotaxi ； 解锁【第一财经智享会员】实时解读 市场动态，把握投资先机。 【第一财经智享会员专属】 【 今 日 速 读 】 精选行业研报，助您捕捉行业风口 【精选快读】 1 .荣耀进军机器人赛道，关注产业链带来的增量机遇 5月2 8日晚间，荣耀CEO李健在回应进军机器人赛道时表示，机器人无疑是公司重点关注的核心赛 道。"我们的核心思路围绕不同场景与用户需求展开，若特定场景需要与相关厂商合作，我们会以 开放姿态推进，同时，荣耀具备自主技术实力，包括长期积累的硬件研发能力与算法优势，这些自 主可控的技术足以支撑新产业的自主开发。" 2025.05.30 点击一键解锁 2. 国内外公司纷纷加码，Robotaxi商业化有望提速 近期，特斯拉、小马智行等多家国内外公司纷纷发布有关Ro b o t a x i的计划。 在当晚的荣耀4 0 0系列发布会上，荣耀展示了一款机器人，跑步速度已经达到4m/s，打破了之前的 机器人行业记录。 万联证券表示，人形机器人产业正处于技术突破与商业化落地的关键节点，政策支持、入局者不断 增加及AI大模型赋能共同推动行业加速发展，2 0 ...